These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38964361)

  • 1. Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial.
    Platt HL; Bruno C; Buntinx E; Pelayo E; Garcia-Huidobro D; Barranco-Santana EA; Sjoberg F; Song JY; Grijalva CG; Orenstein WA; Morgan L; Fernsler D; Xu W; Waleed M; Li J; Buchwald UK;
    Lancet Infect Dis; 2024 Jul; ():. PubMed ID: 38964361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
    Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
    Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial.
    Wassil J; Sisti M; Fairman J; Davis M; Fierro C; Bennett S; Johnson D; Migone TS; Nguyen K; Sauer P; Currie M; Iki S; Simon JK
    Lancet Infect Dis; 2024 Mar; 24(3):308-318. PubMed ID: 38061367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
    Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
    Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study.
    Haranaka M; Yono M; Kishino H; Igarashi R; Oshima N; Sawata M; Platt HL
    Hum Vaccin Immunother; 2023 Aug; 19(2):2228162. PubMed ID: 37389808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.
    Haranaka M; Young Song J; Huang KC; de Solom R; Yamaji M; McElwee K; Kline M; Aizawa M; Peng Y; Scully I; Kogawara O; Gruber WC; Scott DA; Watson W
    Vaccine; 2024 Feb; 42(5):1071-1077. PubMed ID: 38267330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.
    Hurley D; Griffin C; Young M; Scott DA; Pride MW; Scully IL; Ginis J; Severs J; Jansen KU; Gruber WC; Watson W
    Clin Infect Dis; 2021 Oct; 73(7):e1489-e1497. PubMed ID: 32716500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
    Essink B; Sabharwal C; Cannon K; Frenck R; Lal H; Xu X; Sundaraiyer V; Peng Y; Moyer L; Pride MW; Scully IL; Jansen KU; Gruber WC; Scott DA; Watson W
    Clin Infect Dis; 2022 Aug; 75(3):390-398. PubMed ID: 34940806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
    Klein NP; Peyrani P; Yacisin K; Caldwell N; Xu X; Scully IL; Scott DA; Jansen KU; Gruber WC; Watson W
    Vaccine; 2021 Sep; 39(38):5428-5435. PubMed ID: 34315611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.
    Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Bhatla N; Joshi S; Pimple S; Kawade A; Balasubramani L; Thomas A; Suri V; Lalwani S; Uday R; Kamath V; Mandal R; Rajeswar A; Peedicayil A; Poli UR; Banerjee D; Sankaranarayanan R; Basu P; Muwonge R; Gairola S; Dogar V; Rao H; Shaligram U
    Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
    Lupinacci R; Rupp R; Wittawatmongkol O; Jones J; Quinones J; Ulukol B; Dagan R; Richmond P; Stek JE; Romero L; Koseoglu S; Tamms G; McFetridge R; Li J; Cheon K; Musey L; Banniettis N; Bickham K;
    Vaccine; 2023 Jan; 41(5):1142-1152. PubMed ID: 36621410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).
    Wilck M; Cornely OA; Cordonnier C; Velez JD; Ljungman P; Maertens J; Selleslag D; Mullane KM; Nabhan S; Chen Q; Dagan R; Richmond P; Daus C; Geddie K; Tamms G; Sterling T; Patel SM; Shekar T; Musey L; Buchwald UK;
    Clin Infect Dis; 2023 Oct; 77(8):1102-1110. PubMed ID: 37338158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States.
    Fitz-Patrick D; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber W; Watson W
    Hum Vaccin Immunother; 2021 Jul; 17(7):2249-2256. PubMed ID: 33545022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
    Cannon K; Cardona JF; Yacisin K; Thompson A; Belanger TJ; Lee DY; Peng Y; Moyer L; Ginis J; Gruber WC; Scott DA; Watson W
    Vaccine; 2023 Mar; 41(13):2137-2146. PubMed ID: 36828719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
    Simon JK; Staerke NB; Hemming-Harlo M; Layle S; Dagan R; Shekar T; Pedley A; Jumes P; Tamms G; Sterling T; Musey L; Buchwald UK;
    Vaccine; 2022 Feb; 40(9):1342-1351. PubMed ID: 35039194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older.
    Wassil J; Sisti M; Fairman J; Rankin B; Clark J; Bennett S; Johnson D; Migone TS; Nguyen K; Paschenko A; Sauer P; Iki S; Hanson ME; Simon JK
    Vaccine; 2024 Jul; ():. PubMed ID: 39025698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.